You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Follicular lymphomas (FL)

Showing 1 - 25 of 1,772
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed/Refractory B-cell Lymphomas, Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL) Trial in United States

Recruiting
  • Relapsed/Refractory B-cell Lymphomas
  • +11 more
  • CLBR001 and SWI019
  • Duarte, California
  • +7 more
Jul 26, 2022

Follicular Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma Trial in New York (Tazemetostat Pill)

Not yet recruiting
  • Follicular Lymphoma
  • +3 more
  • Tazemetostat Pill
  • New York, New York
    Weill Cornell Medicine/NewYork-Presbyterian Hospital
Jun 28, 2023

DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in Xiamen (Lenalidomide combined with G-CHOP (LO CHOP))

Recruiting
  • DLBCL - Diffuse Large B Cell Lymphoma
  • Follicular Lymphoma
  • Lenalidomide combined with G-CHOP (LO CHOP)
  • Xiamen, Fujian, China
    Bing Xu
Nov 28, 2023

Obinutuzumab-based Therapy for Previously Untreated FL

Recruiting
  • Follicular Lymphoma
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Jun 3, 2023

DLBCL, Chronic Lymphocytic Leukemia, Follicular Lymphoma Trial in New Haven, Worcester, Dallas (ABBV-319)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +2 more
  • New Haven, Connecticut
  • +2 more
Aug 22, 2022

Follicular Lymphoma (FL) Trial in Noblesville (Odronextamab, Rituximab, Cyclophosphamide)

Recruiting
  • Follicular Lymphoma (FL)
  • Noblesville, Indiana
    Investigative Clinical Research of Indiana
Oct 18, 2023

Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Marginal Zone Lymphoma Trial in France (Atezolizumab, Obinutuzumab,

Completed
  • Follicular Lymphoma
  • +3 more
  • Angers, France
  • +24 more
Jan 9, 2023

Follicular Lymphoma (FL) Trial (biological, drug, other)

Not yet recruiting
  • Follicular Lymphoma (FL)
  • Tisagenlecleucel
  • +4 more
  • (no location specified)
May 24, 2023

Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL) Trial (parsaclisib, rituximab, obinutuzumab)

Withdrawn
  • Follicular Lymphoma ( FL)
  • Marginal Zone Lymphoma (MZL)
  • (no location specified)
Jul 14, 2022

Follicular Lymphoma (FL) Trial in Westbury (Odronextamab, Rituximab, Cyclophosphamide)

Recruiting
  • Follicular Lymphoma (FL)
  • Westbury, New York
    Clinical Research Alliance Inc
Oct 13, 2023

Non Hodgkin Lymphoma, Follicular Lymphoma, Relapsed Follicular Lymphoma Trial in Ostrava-, Oslo (Betalutin)

Completed
  • Non Hodgkin Lymphoma
  • +2 more
  • Ostrava-, Porubá, Czechia
  • +1 more
Sep 30, 2022

Follicular Lymphoma, Relapsed and Refractory Follicular Lymphoma Trial in Guangzhou (Orelabrutinib and Rituximab, Orelabrutinib)

Recruiting
  • Follicular Lymphoma
  • Relapsed and Refractory Follicular Lymphoma
  • Guangzhou, Guangdong, China
  • +2 more
Mar 23, 2022

Follicular Lymphoma, Mantle Cell Lymphoma Trial in Rouen (Determination of COVID-19 vacciantion efficacy)

Completed
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • Determination of COVID-19 vacciantion efficacy
  • Rouen, France
    Centre Henri Becquerel
Dec 22, 2022

Obinutuzumab in Combination With Lenalidomide in Relapsed or

Recruiting
  • Follicular Lymphoma
    • Tianjin, China
      Institute of Hematology and Blood Diseases Hospital ,Chinese Aca
    Apr 27, 2023

    Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in Brisbane, Clayton, Heidelberg (Durvalumab, Radiotherapy,

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • Follicular Lymphoma
    • Brisbane, Queensland, Australia
    • +2 more
    Feb 14, 2022

    Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (ONM-501, Cemiplimab)

    Not yet recruiting
    • Triple Negative Breast Cancer
    • +13 more
    • (no location specified)
    Aug 29, 2023

    Lymphoma, Histiocytic Sarcoma, Follicular Dendritic Cell Sarcoma Trial in Chicago, Boston, Omaha (Pembrolizumab)

    Suspended
    • Lymphoma
    • +3 more
    • Chicago, Illinois
    • +3 more
    Jan 30, 2023

    CD5+ Relapsed/Refractory Hematopoietic Malignancies, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL) Trial

    Not yet recruiting
    • CD5+ Relapsed/Refractory Hematopoietic Malignancies
    • +5 more
    • CT125A cells
    • Cyclophosphamide, fludarabine
    • (no location specified)
    Feb 19, 2021

    Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Atlanta (drug, biological,

    Recruiting
    • Grade 1 Follicular Lymphoma
    • +7 more
    • Atlanta, Georgia
      Emory University Hospital/Winship Cancer Institute
    Dec 7, 2021

    Revlimid® Capsules General Drug Use-results Surveillance

    Recruiting
    • Lymphoma Nonhodgkin
      • Japan, Japan
        Local Institution
      Jun 22, 2022

      Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in

      Suspended
      • Recurrent B-Cell Non-Hodgkin Lymphoma
      • +7 more
      • Philadelphia, Pennsylvania
        Sidney Kimmel Cancer Center at Thomas Jefferson University
      Jan 20, 2023

      Follicular Lymphoma Trial in Duarte, Irvine (procedure, other, biological, drug)

      Not yet recruiting
      • Follicular Lymphoma
      • Biospecimen Collection
      • +7 more
      • Duarte, California
      • +1 more
      Oct 27, 2023

      B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (IKS03)

      Not yet recruiting
      • B-cell Non-Hodgkin Lymphoma
      • +4 more
      • (no location specified)
      Dec 7, 2022

      Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

      Not yet recruiting
      • Refractory Aggressive B-cell Lymphomas
      • +12 more
      • Boston, Massachusetts
      • +1 more
      Oct 13, 2022

      DLBCL, MCL, and FL Patients Undergoing CAR Therapy

      Not yet recruiting
      • Follicular Lymphoma
      • +2 more
      • ClonoSEQ
      • Palo Alto, California
        Stanford Cancer Center
      Apr 19, 2022